Enterprise Value
124.2M
Cash
44.22M
Avg Qtr Burn
-7.496M
Short % of Float
1.88%
Insider Ownership
1.49%
Institutional Own.
39.58%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
POSIMIR® (bupivacaine extended-release solution) Details Post Operative Pain | Phase 4 Update | |
DUR-928, larsucosterol Details Liver disease, Alcoholic hepatitis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout |